

# Tobacco Use Is Associated With Increased 90-Day Readmission Among Patients Undergoing Surgery for Degenerative Spine Disease

Michelle Connor, MD<sup>1</sup>, Robert G. Briggs, MD<sup>2</sup>, Phillip A. Bonney, MD<sup>2</sup> , Krista Lamorie-Foote, BA<sup>2</sup>, Kristina Shkirkova, BA<sup>2</sup>, Elliot Min, MD<sup>2</sup>, Li Ding, PhD<sup>2</sup>, William J. Mack, MD<sup>2</sup>, Frank J. Attenello, MD<sup>2</sup>, and John C. Liu, MD<sup>2</sup>

Global Spine Journal  
2022, Vol. 12(5) 787–794  
© The Author(s) 2020  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/2192568220964032  
journals.sagepub.com/home/gsj



## Abstract

**Study Design:** Retrospective database study.

**Objective:** Tobacco use is associated with complications after surgical procedures, including poor wound healing, surgical site infections, and cardiovascular events. We used the Nationwide Readmissions Database (NRD) to determine if tobacco use is associated with increased 30- and 90-day readmission among patients undergoing surgery for degenerative spine disorders.

**Methods:** Patients who underwent elective spine surgery were identified in the NRD from 2010 to 2014. The study population included patients with degenerative spine disorders treated with discectomy, fusion, or decompression. Descriptive and multivariate logistic regression analyses were performed to identify patient and hospital factors associated with 30- and 90-day readmission, with significance set at  $P$  value  $< .001$ .

**Results:** Within 30 days, 4.8% of patients were readmitted at a median time of 9 days. The most common reasons for 30-day readmission were postoperative infection (12.5%), septicemia (3.5%), and postoperative pain (3.0%). Within 90 days, 7.3% were readmitted at a median time of 18 days. The most common reasons for 90-day readmission were postoperative infection (9.6%), septicemia (3.5%), and pneumonia (2.3%). After adjustment for patient and hospital characteristics, tobacco use was independently associated with readmission at 90 days (odds ratio 1.05, 95% confidence interval 1.03-1.07,  $P < .0001$ ) but not 30 days (odds ratio 1.02, 95% confidence interval 1.00-1.05,  $P = .045$ ).

**Conclusions:** Tobacco use is associated with readmission within 90 days after cervical and thoracolumbar spine surgery for degenerative disease. Tobacco use is a known risk factor for adverse health events and therefore should be considered when selecting patients for spine surgery.

## Keywords

complications, discectomy, fusion, hospital, laminectomy, readmission, smoking, spine surgery, tobacco

## Introduction

Cigarette smoking is a leading problem in public health that impacts an estimated 34.3 million adults in the United States.<sup>1,2</sup> Increasing evidence has shown that tobacco use results in worse outcomes after surgery, and studies have sought to characterize the effect of tobacco use on perioperative morbidity and mortality.<sup>3,4</sup> Such complications have been demonstrated in both institutional and database studies in a number of surgical disciplines, including general,<sup>5</sup> plastic,<sup>5,6</sup> head and neck,<sup>7</sup>

orthopedic,<sup>8,9</sup> and cardiac.<sup>10</sup> Within cranial neurosurgery, tobacco use has been associated with increased intraoperative

<sup>1</sup> Washington University, St Louis, MO, USA

<sup>2</sup> University of Southern California, Los Angeles, CA, USA

### Corresponding Author:

Phillip A. Bonney, MD, Department of Neurosurgery, University of Southern California, 1200 N State St., Ste. 3300, Los Angeles, CA 90033, USA.  
Email: phil.alan.bonney@gmail.com



blood loss and wound complications.<sup>11,12</sup> Furthermore, in the spine literature, tobacco use has been associated with increased rates of pseudoarthrosis, infection, and wound complications.<sup>13-16</sup>

Readmission is an important measure of patient outcome and hospital performance, and hospitals may be penalized for higher-than-average readmission rates through the Hospital Readmission Reduction Program (HRRP).<sup>17</sup> Accordingly, increasing attention has been paid to understand factors associated with readmission and to develop strategies to reduce readmission. Studies examining readmission after spine surgery have previously identified comorbid conditions, older age, and postoperative complications<sup>18-23</sup> as factors associated with readmission.

This study used the Nationwide Readmissions Database (NRD) from 2010 to 2014 to measure 30- and 90-day readmission rates and identify factors related to readmission after degenerative spine surgery. We examined whether tobacco use was independently associated with readmission after adjusting for patient and hospital factors.

## Methods

### Database

This is a retrospective study utilizing the NRD, a nationally representative database that is maintained through the Healthcare Cost and Utilization Project. The NRD includes data on approximately 50% of all hospitalizations and readmissions in the United States. Each patient in the NRD has a unique identifier link that is used to determine patient hospitalizations and discharges within a calendar year. The NRD was queried from 2010 to 2014. The study period was selected to include the last 5 years of International Classification of Diseases, Diagnosis, and Procedure codes (ICD-9-CM, ICD-9-PCS), prior to the transition to ICD-10 in 2015. Institutional review board approval was not required for this review.

### Study Population

Patients aged 18 and older who underwent elective decompression, discectomy, or fusion for cervical or thoracolumbar degenerative spine diseases were included in the study. Patients were identified using ICD-9 diagnosis and procedure codes (Table 1), in accordance with other studies.<sup>24</sup> Patients with traumatic injuries or nondegenerative spine diseases were excluded. Patients who died during index hospitalization were excluded. Patients with missing data for survival or length of stay were also excluded. To allow for sufficient follow-up time, patients discharged in January to November were included in the 30-day readmission cohort; patients discharged in January to September were included in 90-day readmission cohort. As such, fewer patients are represented in the latter group. For patients with multiple readmissions in the study period, only the first nonelective readmission was studied.

**Table 1.** ICD-9 Diagnosis and Procedure Codes.

#### ICD-9 diagnosis codes

721.0: Cervical spondylosis without myelopathy  
 721.1: Cervical spondylosis with myelopathy  
 721.3: Lumbosacral spondylosis without myelopathy  
 721.41: Spondylosis with myelopathy, thoracic region  
 721.42: Spondylosis with myelopathy, lumbar region  
 722.0: Displacement of cervical intervertebral disc without myelopathy  
 722.10: Displacement of lumbar intervertebral disc without myelopathy  
 722.11: Displacement of thoracic intervertebral disc without myelopathy  
 722.4: Degeneration of cervical intervertebral disc  
 722.51: Degeneration of thoracic or thoracolumbar intervertebral disc  
 722.52: Degeneration of lumbar or lumbosacral intervertebral disc  
 722.71: Intervertebral disc disorder with myelopathy, cervical region  
 722.72: Intervertebral disc disorder with myelopathy, thoracic region  
 722.73: Intervertebral disc disorder with myelopathy, lumbar region  
 722.81: Postlaminectomy syndrome, cervical region  
 723.0: Spinal stenosis in cervical region  
 723.1: Cervicalgia  
 723.4: Brachial neuritis or radiculitis NOS  
 723.7: Ossification of posterior longitudinal ligament in cervical region  
 724.2: Lumbago  
 738.2: Acquired deformity of neck  
 738.4: Acquired spondylolisthesis

#### ICD-9 procedure codes

80.50: Excision or destruction of intervertebral disc, unspecified  
 80.51: Excision of intervertebral disc  
 81.00: Spinal fusion, not otherwise specified  
 81.01: Atlas-axis spinal fusion  
 81.02: Other cervical fusion of the anterior column, anterior technique  
 81.03: Other cervical fusion of the posterior column, posterior technique  
 81.04: Dorsal and dorsolumbar fusion of the anterior column, anterior technique  
 81.05: Dorsal and dorsolumbar fusion of the posterior column, posterior technique  
 81.06: Lumbar and lumbosacral fusion of the anterior column, anterior technique  
 81.07: Lumbar and lumbosacral fusion of the posterior column, posterior technique  
 81.08: Lumbar and lumbosacral fusion of the anterior column, posterior technique  
 81.31: Refusion of atlas-axis spine  
 81.32: Refusion of other cervical spine, anterior column, anterior technique  
 81.33: Refusion of other cervical spine, posterior column, posterior technique  
 81.34: Refusion of dorsal and dorsolumbar spine, anterior column, anterior technique  
 81.35: Refusion of dorsal and dorsolumbar spine, posterior column, posterior technique  
 81.36: Refusion of lumbar and lumbosacral spine, anterior column, anterior technique  
 81.37: Refusion of lumbar and lumbosacral spine, posterior column, posterior technique  
 81.38: Refusion of lumbar and lumbosacral spine, anterior column, posterior technique  
 81.62: Fusion or refusion of 2-3 vertebrae  
 81.63: Fusion or refusion of 4-8 vertebrae  
 03.09: Other exploration and decompression of spinal canal

Abbreviation: ICD-9, International Classification of Diseases, 9th Revision.

### Patient and Hospital Variables

Patient and hospital variables available in the database were chosen to include in the model based on relevant risk factors previously associated with readmission after spine surgery.

Patient demographic factors included gender (male, female), patient age (18-44, 45-59, 60-74, or ≥75 years old), primary insurance type (Medicare, Medicaid, private insurance, self-pay, no-charge, other), median household income (0-25, 26-50, 51-75, 76-100 percentile), length of stay (0-1, 2, 3-4, ≥5 days), and discharge disposition (routine, short-term hospital, transfer, home health care, against medical advice).

In addition, patient comorbidities previously associated with readmission or poor surgical outcomes were identified using the NRD or ICD-9 codes and included presence of Elixhauser comorbidity (yes, no), presence of a medical or neurological complication during initial hospitalization (intracerebral hemorrhage [431.998.11-12], seizures [345.xx], neurological complications after procedure [997.01 997.09]), tobacco use (305.1, V15.82), obesity (278.0, V85.3-V85.4), steroid use (V58.65), systemic inflammatory response syndrome (995.9x, 785.52), chronic lung disease, ventilator dependence (V46.1x), history of chemotherapy (V58.11, V87.41), diabetes (250.xx), and hypercoagulable state (289.81). Hospital variables included procedure volume (>/<90th percentile), hospital bed size (small, medium, large), hospital location (urban, rural), and teaching status (teaching, nonteaching).

**Statistical Analysis**

Descriptive statistics were used to characterize patient and hospital factors. These factors were then included in a multivariate logistic regression analysis to determine which of these were associated with 30- and 90-day readmissions. Generalized Estimation Equation was used to account for hospital clustering. We used odds ratios (ORs) and 95% confidence intervals (CIs) to report these results, with statistical significance defined as *P* < .001. Statistical analyses were performed using SAS 9.4 (SAS Inc).

**Results**

**Study Population**

A total of 703 051 patients were identified in the 90-day model who underwent surgery for degenerative disease of the cervical or thoracolumbar spine (Table 2). Surgery for degenerative disease of the thoracolumbar spine comprised the majority of operations (61.5%). Overall, 29.0% of patients were tobacco users.

The overall readmission rate was 4.8% within 30 days and 7.3% within 90 days. The most common reasons for readmission were postoperative infection (12.5% and 9.6% of primary readmission diagnoses, respectively), septicemia (3.5% and 3.5%, respectively), and pneumonia (2.4% and 2.3%, respectively; Table 3).

**Tobacco Use Is Associated With 90-Day Readmission**

After adjustment for patient- and hospital-level factors, tobacco use was independently associated with increased likelihood of readmission within 90 days (OR 1.05, 95% CI 1.03-1.07,

**Table 2.** Demographics for Readmission Within 90 Days.

| Characteristic                                    | Tobacco use<br>(n = 203 323) | Total<br>(n = 703 051) | <i>P</i> |
|---|------------------------------|------------------------|----------|
| <b>Anatomic location, n (%)</b>                   |                              |                        |          |
| Cervical  | 83 753 (41.2)                | 270 361 (38.5)         | <.0001   |
| Thoracolumbar                                     | 119 570 (58.8)               | 432 690 (61.5)         |          |
| <b>Age, n (%)</b>                                 |                              |                        |          |
| 18-44   | 43 319 (21.3)                | 138 397 (19.7)         | <.0001   |
| 45-59   | 82 142 (40.0)                | 253 887 (36.1)         |          |
| 60-74   | 62 663 (30.8)                | 235 885 (33.6)         |          |
| ≥75   | 15 199 (7.5)                 | 74 882 (10.7)          |          |
| <b>Gender, n (%)</b>                              |                              |                        |          |
| Male  | 109 573 (53.9)               | 344 007 (48.9)         | <.0001   |
| Female  | 93 750 (46.1)                | 359 044 (51.1)         |          |
| <b>Primary insurance, n (%)</b>                   |                              |                        |          |
| Medicare  | 73 640 (36.2)                | 263 447 (37.5)         | <.0001   |
| Medicaid  | 18 610 (9.2)                 | 42 425 (6.0)           |          |
| Private insurance                                 | 78 662 (38.7)                | 297 726 (42.3)         |          |
| Self-pay  | 3932 (1.9)                   | 9715 (1.4)             |          |
| No charge   | 667 (0.3)                    | 1537 (0.2)             |          |
| Other   | 27 266 (13.4)                | 85 831 (12.2)          |          |
| Missing   | 546 (0.3)                    | 2370 (0.3)             |          |
| <b>Median household income<sup>a</sup>, n (%)</b> |                              |                        |          |
| 0-25 percentile                                   | 51 890 (25.5)                | 159 106 (22.6)         | <.0001   |
| 26-50 percentile                                  | 53 361 (26.2)                | 169 459 (24.1)         |          |
| 51-75 percentile                                  | 51 471 (25.3)                | 181 858 (25.9)         |          |
| 76-100 percentile                                 | 42 920 (21.1)                | 179 555 (25.5)         |          |
| Missing   | 3681 (1.8)                   | 13 073 (1.9)           |          |
| <b>Elixhauser comorbidity, n (%)</b>              |                              |                        |          |
| Yes   | 144 640 (71.1)               | 476 031 (67.7)         | <.0001   |
| No  | 58 683 (28.9)                | 227 020 (32.3)         |          |
| <b>Diabetes, n (%)</b>                            |                              |                        |          |
| Yes   | 35 393 (17.4)                | 126 410 (18.0)         | <.0001   |
| No  | 167 930 (82.6)               | 576 641 (82.0)         |          |
| <b>Chronic lung disease, n (%)</b>                |                              |                        |          |
| Yes   | 45 666 (22.5)                | 106 219 (15.1)         | <.0001   |
| No  | 157 657 (77.5)               | 596 832 (84.9)         |          |
| <b>Obesity, n (%)</b>                             |                              |                        |          |
| Yes   | 722 (0.4)                    | 2762 (0.4)             | .0012    |
| No  | 202 601 (99.6)               | 700 289 (99.6)         |          |
| <b>Hypercoagulable state, n (%)</b>               |                              |                        |          |
| Yes   | 412 (0.2)                    | 1461 (0.2)             | .54      |
| No  | 202 911 (99.8)               | 701 590 (99.8)         |          |
| <b>Steroid use, n (%)</b>                         |                              |                        |          |
| Yes   | 2124 (1.0)                   | 6038 (0.9)             | <.0001   |
| No  | 201 199 (99.0)               | 697 013 (99.1)         |          |
| <b>History of chemotherapy, n (%)</b>             |                              |                        |          |
| Yes   | 491 (0.2)                    | 1313 (0.2)             | <.0001   |
| No  | 202 832 (99.8)               | 701 738 (99.8)         |          |
| <b>Venous thromboembolism, n (%)</b>              |                              |                        |          |
| Yes   | 5174 (2.5)                   | 17 170 (2.4)           | .0004    |
| No  | 198 149 (97.5)               | 685 881 (97.6)         |          |
| <b>Hospital bed size, n (%)</b>                   |                              |                        |          |
| Small   | 21 231 (10.4)                | 79 498 (11.3)          | <.0001   |
| Medium  | 49 235 (24.2)                | 169 530 (24.1)         |          |
| Large   | 132 857 (65.3)               | 454 023 (64.6)         |          |
| <b>Hospital teaching status, n (%)</b>            |                              |                        |          |
| Teaching  | 116 155 (57.1)               | 386 203 (54.9)         | <.0001   |
| Nonteaching                                       | 87 168 (42.9)                | 316 848 (45.1)         |          |

(continued)

**Table 2.** (continued)

| Characteristic                      | Tobacco use<br>(n = 203 323) | Total<br>(n = 703 051) | P      |
|-------------------------------------|------------------------------|------------------------|--------|
| Hospital volume, n (%)              |                              |                        |        |
| >90th percentile                    | 79 351 (39.0)                | 265 715 (37.8)         | <.0001 |
| ≤90th percentile <sup>b</sup>       | 123 972 (61.0)               | 437 336 (62.2)         |        |
| SIRS criteria, n (%)                |                              |                        |        |
| Yes                                 | 775 (0.4)                    | 2930 (0.4)             | .003   |
| No                                  | 202 548 (99.6)               | 700 121 (99.6)         |        |
| Medical complication, n (%)         |                              |                        |        |
| Yes                                 | 3096 (1.5)                   | 11 466 (1.6)           | <.0001 |
| No                                  | 200 227 (98.5)               | 691 585 (98.4)         |        |
| Neurological complication,<br>n (%) |                              |                        |        |
| Yes                                 | 5508 (2.7)                   | 16 691 (2.4)           | <.0001 |
| No                                  | 197 815 (97.3)               | 686 360 (97.6)         |        |
| Disposition, n (%)                  |                              |                        |        |
| Routine                             | 154 762 (76.1)               | 527 273 (75.0)         | <.0001 |
| Short-term hospital                 | 697 (0.3)                    | 2810 (0.4)             |        |
| Transfer                            | 16 576 (8.2)                 | 65 308 (9.3)           |        |
| Home health care                    | 30 945 (15.2)                | 106 929 (15.2)         |        |
| Against medical advice              | 334 (0.2)                    | 676 (0.1)              |        |
| Missing                             | DS <sup>c</sup>              | 55 (0.0)               |        |
| Index length of stay, n (%)         |                              |                        |        |
| 0-1 days                            | 70 896 (34.9)                | 244 466 (34.8)         | <.0001 |
| 2 days                              | 40 746 (20.0)                | 139 056 (19.8)         |        |
| 3-4 days                            | 53 817 (26.5)                | 188 437 (26.8)         |        |
| ≥5 days                             | 37 864 (18.6)                | 131 092 (18.6)         |        |

<sup>a</sup>For patient's ZIP code, based on current year.

<sup>b</sup>A total of 652 procedures/year.

<sup>c</sup>Data suppressed for patient confidentiality.

**Table 3.** Primary Diagnoses for 30- and 90-Day Readmission.

| ICD-9 diagnosis                          | 30 Days, n (%);<br>N = 40 841 | 90 Days, n (%);<br>N = 51 473 |
|--|-------------------------------|-------------------------------|
| 998.59 Postoperative infection           | 5090 (12.5)                   | 4959 (9.6)                    |
| 038.9 Septicemia                         | 1431 (3.5)                    | 1821 (3.5)                    |
| 338.18 Acute postoperative pain          | 1230 (3.0)                    | 1200 (2.3)                    |
| 998.12 Hematoma complicating a procedure | 1220 (3.0)                    | 1090 (2.1)                    |
| 486 Pneumonia                            | 970 (2.4)                     | 1065 (2.1)                    |
| 415.19 Pulmonary embolism and infarction | 942 (2.3)                     | 1051 (2.0)                    |
| 998.13 Seroma complicating a procedure   | 931 (2.3)                     | 980 (1.9)                     |
| 599.0 Urinary tract infection            | 736 (1.8)                     | 958 (1.9)                     |
| 584.9 Acute renal failure                | 704 (1.7)                     | 893 (1.7)                     |
| 722.10 Lumbar disc displacement          | 677 (1.7)                     | 846 (1.6)                     |

Abbreviation: ICD-9, International Classification of Diseases, 9th Revision.

$P < .0001$ ). Tobacco use did not meet our preset threshold for significance at 30 days (OR 1.02, 95% CI 1.00-1.05,  $P = .045$ ; Table 4).

Other comorbidities associated with readmission included older age, male gender, chronic lung disease, diabetes, obesity,

venous thromboembolism, hypercoagulability, steroid use, and history of chemotherapy. Insurance other than Medicaid was associated with decreased readmission. Hospitalization factors included SIRS criteria, medical complications, neurological complications, increased index length of stay, and disposition other than routine were associated with increased readmission, while smaller hospital bed size was associated with decreased readmission.

## Discussion

This study leveraged the NRD from 2010 to 2014 to investigate tobacco use and other factors associated with 30-day and 90-day readmissions following cervical and thoracolumbar degenerative spine surgery. In this cohort, 4.8% and 7.3% of patients were readmitted within 30 and 90 days, respectively. After adjusting for common causes of readmission, tobacco use was independently associated with readmission within 90 days but not 30 days based on our preset threshold for significance. Postoperative complications including infection contributed to readmissions.

Readmission rates in this study were similar to those reported in other studies for patients undergoing spine surgery. A previous NRD study from January to September 2013 reported a 30-day readmission rate of 5.4% and a 90-day readmission rate of 10% for patients following elective posterior cervical spine surgery for degenerative conditions.<sup>25</sup> Additional studies have estimated 30-day readmission rates between 3.2% and 12.9% and 90-day readmission rates between 5.6% and 12.7%.<sup>13,19-22,26-29</sup> This study is the first to isolate the effect of tobacco use on readmission among spine patients.

Surprisingly, prior retrospective studies in specific subsets of patients have failed to find an association between tobacco use and readmission. For example, a single-institution analysis of 839 patients undergoing elective complex spinal fusion did not find an association between tobacco use and readmission.<sup>26</sup> Similarly, there was no association between tobacco use and readmission in 2207 patients undergoing surgery for spinal tumors.<sup>19</sup> Last, a study of 2761 patients readmitted within 90 days following spine surgery for degenerative disease found no association in multivariable analysis.<sup>28</sup> These studies differ from the current study in that the sizes of the cohorts were smaller, which may explain the difference.

Postoperative complications such as infection, septicemia, and pain were the most common reasons for readmission in this study. Tobacco use is a known risk factor for these adverse health events. Tobacco use has been shown to increase surgical site infections following spine surgery.<sup>15,30-33</sup> The same trend has been noted in additional surgical specialties.<sup>6-8,10</sup> When investigating all surgeries, tobacco use has been associated with increased rates of sepsis and 30-day mortality.<sup>32</sup> Given these reports, it is surprising that there was not a clear relationship between tobacco use and 30-day readmission in this study. Nonetheless, studies have suggested that factors intrinsic to tobacco use may contribute to delayed wound healing and increased risk of infection. For example, nicotine induces

**Table 4.** Summary of Associations with 30- and 90-Day Readmission.

| Characteristic            | 30-Day readmission |        | 90-Day readmission |        |
|---------------------------|--------------------|--------|--------------------|--------|
|                           | OR (95% CI)        | P      | OR (95% CI)        | P      |
| Tobacco use               | 1.02 (1.00-1.05)   | .045   | 1.05 (1.03-1.07)   | <.0001 |
| Age                       |                    |        |                    |        |
| 18-44                     | Ref                |        | Ref                |        |
| 45-59                     | 1.05 (1.02-1.09)   | .004   | 1.05 (1.02-1.08)   | .0024  |
| 60-74                     | 1.11 (1.07-1.15)   | <.0001 | 1.05 (1.01-1.09)   | .0097  |
| ≥75                       | 1.25 (1.19-1.31)   | <.0001 | 1.22 (1.17-1.27)   | <.0001 |
| Female gender             | 0.90 (0.88-0.91)   | <.0001 | 0.90 (0.89-0.92)   | <.0001 |
| Primary insurance         |                    |        |                    |        |
| Medicare                  | 0.83 (0.80-0.87)   | <.0001 | 0.83 (0.79-0.86)   | <.0001 |
| Medicaid                  | Ref                |        | Ref                |        |
| Private insurance         | 0.60 (0.57-0.63)   | <.0001 | 0.55 (0.53-0.58)   | <.0001 |
| Self-pay                  | 0.81 (0.73-0.89)   | <.0001 | 0.78 (0.72-0.85)   | <.0001 |
| No charge                 | 0.92 (0.75-1.13)   | .42    | 1.01 (0.84-1.21)   | .95    |
| Other                     | 0.61 (0.58-0.64)   | <.0001 | 0.55 (0.53-0.58)   | <.0001 |
| Elixhauser comorbidity    | 1.23 (1.20-1.27)   | <.0001 | 1.25 (1.21-1.28)   | <.0001 |
| Chronic lung disease      | 1.21 (1.18-1.24)   | <.0001 | 1.27 (1.24-1.30)   | <.0001 |
| Diabetes                  | 1.25 (1.22-1.28)   | <.0001 | 1.27 (1.25-1.30)   | <.0001 |
| Obesity                   | 1.31 (1.13-1.52)   | .0004  | 1.21 (1.06-1.38)   | .0053  |
| Venous thromboembolism    | 1.52 (1.44-1.59)   | <.0001 | 1.51 (1.45-1.58)   | <.0001 |
| Hypercoagulable state     | 1.25 (1.06-1.48)   | .0095  | 1.32 (1.12-1.55)   | .0009  |
| Steroid use               | 1.37 (1.26-1.50)   | <.0001 | 1.47 (1.35-1.59)   | <.0001 |
| History of chemotherapy   | 1.47 (1.24-1.74)   | <.0001 | 1.64 (1.41-1.91)   | <.0001 |
| SIRS criteria             | 1.41 (1.28-1.55)   | <.0001 | 1.55 (1.41-1.70)   | <.0001 |
| Medical complication      | 1.39 (1.32-1.47)   | <.0001 | 1.47 (1.40-1.54)   | <.0001 |
| Neurological complication | 1.40 (1.34-1.47)   | <.0001 | 1.44 (1.38-1.51)   | <.0001 |
| Index length of stay      |                    |        |                    |        |
| 0-1 days                  | Ref                |        | Ref                |        |
| 2 days                    | 1.34 (1.29-1.39)   | <.0001 | 1.30 (1.26-1.34)   | <.0001 |
| 3-4 days                  | 1.53 (1.48-1.58)   | <.0001 | 1.44 (1.39-1.48)   | <.0001 |
| ≥5 days                   | 2.41 (2.32-2.50)   | <.0001 | 2.32 (2.25-2.40)   | <.0001 |
| Disposition               |                    |        |                    |        |
| Routine                   | Ref                |        | Ref                |        |
| Short-term hospital       | 2.33 (2.05-2.73)   | <.0001 | 2.43 (1.15-2.74)   | <.0001 |
| Transfer                  | 1.74 (1.69-1.80)   | <.0001 | 1.90 (1.84-1.95)   | <.0001 |
| Home health care          | 1.23 (1.20-1.27)   | <.0001 | 1.23 (1.19-1.27)   | <.0001 |
| Against medical advice    | 2.66 (2.17-3.27)   | <.0001 | 2.36 (1.93-2.90)   | <.0001 |
| Hospital bed size         |                    |        |                    |        |
| Small                     | 0.88 (0.82-0.94)   | .0002  | 0.87 (0.81-0.93)   | <.0001 |
| Medium                    | 0.97 (0.94-1.00)   | .051   | 0.95 (0.92-0.98)   | .0006  |
| Large                     | Ref                |        | Ref                |        |

Abbreviations: OR, odds ratio; CI, confidence interval; SIRS, systemic inflammatory response syndrome.

vasoconstriction and tissue hypoxia, disrupting angiogenesis, and cigarette smoke impairs neutrophil and monocyte migration and chemotaxis.<sup>26,34</sup> A retrospective study leveraging the National Surgical Quality Improvement (NSQI) database from 2012 to 2014 found that surgical site infections were the most common cause for readmission after spine surgery.<sup>20</sup> Tobacco use thus likely contributes to readmissions by increasing the risk and incidence of infection.

Smokers also exhibit poorer outcomes, increased postoperative pain, and decreased satisfaction following spinal surgery.<sup>35,36</sup> Two years following surgery for lumbar spine stenosis, smokers had a higher Oswestry Disability Index (a marker of inferior quality of life), increased leg and back pain,

and decreased walking ability compared to nonsmokers.<sup>35</sup> This suggests that long-term outcomes in smokers are also affected.

Some studies with smaller sample sizes have failed to identify an association between tobacco use status and postoperative complications. A retrospective study of patients following spinal fusion found no difference in 30-day complication rates including pain, wound dehiscence, and wound drainage in smokers compared to nonsmokers.<sup>26</sup> A study utilizing the NSQI from 2006 to 2010 found no association between tobacco use and major complications after elective spine surgery, but patients who were current smokers with more than 60 pack-year histories were more likely to die within 30 days of surgery.<sup>37</sup> This suggests that the adverse effects of tobacco use

may to some extent be dose dependent. Unfortunately, the NRD does not stratify details of tobacco use such as pack-year history.

It has long been advocated that smoking cessation should be encouraged prior to spine surgery. Studies have suggested that up to 75% of tobacco users who undergo surgery have the desire to quit.<sup>3,38</sup> Patients who quit tobacco use after surgery for longer than 6 months following spinal fusion had decreased rates of nonunion and increased patient satisfaction and return to work rates compared to those who continued to smoke.<sup>39,40</sup> In one orthopedic study, preoperative smoking intervention 6 to 8 weeks before surgery, including cessation counseling and nicotine replacement therapy, was associated with decreased postoperative complication rates in patients undergoing hip or knee alloplasty.<sup>41</sup> Across surgical specialties, one meta-analysis found that preoperative tobacco use cessation was associated with a 41% risk reduction of postoperative complications.<sup>42</sup>

### Limitations

This retrospective study utilized the NRD, which is subject to coding errors and information bias. The NRD may underestimate true readmission rates, as it only contains data on patients who were readmitted in the same state. In addition, this study is limited by the ICD-9 diagnosis and procedure codes available through the NRD. To overcome this limitation, we included numerous diagnoses and surgical procedures in this study to ensure a heterogeneous group of patients undergoing degenerative spine surgery were included in the analysis. As a result of this, conclusions cannot be drawn regarding the effects of tobacco use on specific spine surgeries and patient conditions. Relatedly, the lack of granularity on surgical details precludes the specific study of factors such as surgical time and incision size which are related to complication rates. Additionally, due to the transition in ICD coding between the 9th and 10th editions, our analysis does not include the most recent years (2015-2017) of NRD data.

As both current and former tobacco users were included in this study, the effect of tobacco use cessation cannot be quantified by this type of analysis. Given that pre- and postoperative smoking cessation have been shown to decrease rates of postoperative complications, it is possible that the effect of tobacco use on rates of readmission may be even higher in active smokers. Finally, this study did not separately assess the use of e-cigarettes. More study is warranted for this increasingly prevalent condition.

### Conclusions

This study identified tobacco use as a modifiable risk factor for readmission after elective spine surgery for degenerative conditions. These data be used to aid in patient selection and preoperative planning.


### Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Mack—Consultant: Rebound Therapeutics, Viseon Imperative Care, Q'Apel, Medtronic, Stryker, Stream Biomedical, Spartan Micro; Investor: Cerebrotech, Endostream, Viseon, Rebound, Q'Apel, and Spartan Micro. Dr Liu—Viseon (consultancy). The authors declare no additional disclosures or conflicts of interest related to this work.

### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### ORCID iD

Phillip A. Bonney, MD  <https://orcid.org/0000-0003-4716-9906>

### References

- Centers for Disease Control and Prevention. Current cigarette smoking among adults in the United States. Published November 18, 2019. Accessed July 21, 2020. [https://www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/adult\\_data/cig\\_smoking/index.htm](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm)
- Creamer MR, Wang TW, Babb S, et al. Tobacco product use and cessation indicators among adults—United States, 2018. *MMWR Morb Mortal Wkly Rep*. 2019;68:1013-1019. doi:10.15585/mmwr.mm6845a2
- Khullar D, Maa J. The impact of smoking on surgical outcomes. *J Am Coll Surg*. 2012;215:418-426. doi:10.1016/j.jamcollsurg.2012.05.023
- Turan A, Mascha EJ, Roberman D, et al. Smoking and perioperative outcomes. *Anesthesiology*. 2011;114:837-846. doi:10.1097/ALN.0b013e318210f560
- Fu RH, Toyoda Y, Li L, Baser O, Rohde CH, Otterburn DM. Smoking and postoperative complications in plastic and general surgical procedures: a propensity score-matched analysis of 294903 patients from the National Surgical Quality Improvement Program Database from 2005 to 2014. *Plast Reconstr Surg*. 2018;142:1633-1643. doi:10.1097/PRS.00000000000005008
- Goltsman D, Munabi NCO, Ascherman JA. The association between smoking and plastic surgery outcomes in 40465 patients: an analysis of the American College of Surgeons National Surgical Quality Improvement Program Data Sets. *Plast Reconstr Surg*. 2017;139:503-511. doi:10.1097/PRS.0000000000002958
- Hatcher JL, Sterba KR, Tooze JA, et al. Tobacco use and surgical outcomes in patients with head and neck cancer. *Head Neck*. 2016;38:700-706. doi:10.1002/hed.23944
- Duchman KR, Gao Y, Pugely AJ, Martin CT, Noiseux NO, Callaghan JJ. The effect of smoking on short-term complications following total hip and knee arthroplasty. *J Bone Joint Surg Am*. 2015;97:1049-1058. doi:10.2106/JBJS.N.01016
- Singh JA, Houston TK, Ponce BA, et al. Smoking as a risk factor for short-term outcomes following primary total hip and total knee replacement in veterans. *Arthritis Care Res (Hoboken)*. 2011;63:1365-1374. doi:10.1002/acr.20555
- Jones R, Nyawo B, Jamieson S, Clark S. Current smoking predicts increased operative mortality and morbidity after cardiac surgery

- in the elderly. *Interact Cardiovasc Thorac Surg*. 2011;12:449-453. doi:10.1510/icvts.2010.239863
11. Lau D, Berger MS, Khullar D, Maa J. The impact of smoking on neurosurgical outcomes. *J Neurosurg*. 2013;119:1323-1330. doi:10.3171/2013.5.JNS122287
  12. Rock AK, Opalak CF, Workman KG, Broaddus WC. Safety outcomes following spine and cranial neurosurgery: evidence from the National Surgical Quality Improvement Program. *J Neurosurg Anesthesiol*. 2018;30:328-336. doi:10.1097/ANA.0000000000000474
  13. Berman D, Oren JH, Bendo J, Spivak J. The effect of smoking on spinal fusion. *Int J Spine Surg*. 2017;11:29. doi:10.14444/4029
  14. Durand WM, DePasse JM, Bokshan SL, Eltorai AEM, Daniels AH. Tobacco use and complications following spinal fusion: a comparison of the National Surgical Quality Improvement Program and National Inpatient Sample Datasets. *World Neurosurg*. 2019;123:e393-e407. doi:10.1016/j.wneu.2018.11.180
  15. Echt M, De la Garza Ramos R, Nakhla J, et al. The effect of cigarette smoking on wound complications after single-level posterolateral and interbody fusion for spondylolisthesis. *World Neurosurg*. 2018;116:e824-e829. doi:10.1016/j.wneu.2018.05.103
  16. Kong L, Liu Z, Meng F, Shen Y. Smoking and risk of surgical site infection after spinal surgery: a systematic review and meta-analysis. *Surg Infect (Larchmt)*. 2017;18:206-214. doi:10.1089/sur.2016.209
  17. Centers for Medicare & Medicaid Services. *Hospital Readmissions Reduction Program (HRRP)*. Accessed July 21, 2020. <https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program>
  18. Saleh A, Thirukumaran C, Mesfin A, Molinari RW. Complications and readmission after lumbar spine surgery in elderly patients: an analysis of 2320 patients. *Spine J*. 2017;17:1106-1112. doi:10.1016/j.spinee.2017.03.019
  19. Karhade AV, Vasudeva VS, Dasenbrock HH, et al. Thirty-day readmission and reoperation after surgery for spinal tumors: a National Surgical Quality Improvement Program analysis. *Neurosurg Focus*. 2016;41:E5. doi:10.3171/2016.5.FOCUS16168
  20. Piper K, DeAndrea-Lazarus I, Algattas H, et al. Risk factors associated with readmission and reoperation in patients undergoing spine surgery. *World Neurosurg*. 2018;110:e627-e635. doi:10.1016/j.wneu.2017.11.057
  21. Derman PB, Lampe LP, Pan TJ, et al. Postoperative emergency department utilization and hospital readmission after cervical spine arthrodesis: rates, trends, causes, and risk factors. *Spine (Phila Pa 1976)*. 2018;43:1031-1037. doi:10.1097/BRS.0000000000002518
  22. Bernstein DN, Thirukumaran C, Saleh A, Molinari RW, Mesfin A. Complications and readmission after cervical spine surgery in elderly patients: an analysis of 1786 patients. *World Neurosurg*. 2017;103:859-868.e8. doi:10.1016/j.wneu.2017.04.109
  23. Phan K, Ranson W, White SJW, et al. Thirty-day perioperative complications, prolonged length of stay, and readmission following elective posterior lumbar fusion associated with poor nutritional status. *Global Spine J*. 2019;9:417-423. doi:10.1177/2192568218797089
  24. Buchanan IA, Lin M, Donoho DA, et al. Venous thromboembolism after degenerative spine surgery: a nationwide readmissions database analysis. *World Neurosurg*. 2019;125:e165-e174. doi:10.1016/j.wneu.2019.01.029
  25. Rumalla K, Smith KA, Arnold PM. National rates, causes, risk factors, and outcomes associated with 30-day and 90-day readmissions following degenerative posterior cervical spine surgery utilizing the nationwide readmissions database. *Neurosurgery*. 2017;81:740-751. doi:10.1093/neuros/nyx063
  26. Elsamadicy AA, Adogwa O, Sergesketter A, et al. Reduced impact of smoking status on 30-day complication and readmission rates after elective spinal fusion ( $\geq 3$  levels) for adult spine deformity: a single institutional study of 839 patients. *World Neurosurg*. 2017;107:233-238. doi:10.1016/j.wneu.2017.07.174
  27. Schoenfeld AJ, Sturgeon DJ, Blucher JA, Haider AH, Kang JD. Alterations in 90-day morbidity, mortality, and readmission rates following spine surgery in Medicare Accountable Care Organizations (2009-2014). *Spine J*. 2019;19:8-14. doi:10.1016/j.spinee.2018.06.367
  28. Hills J, Sivaganesan A, Khan I, et al. Causes and timing of unplanned 90-day readmissions following spine surgery. *Spine (Phila Pa 1976)*. 2018;43:991-998. doi:10.1097/BRS.00000000000002535
  29. Adogwa O, Elsamadicy AA, Han JL, Karikari IO, Cheng J, Bagley CA. 30-day readmission after spine surgery: an analysis of 1400 consecutive spine surgery patients. *Spine (Phila Pa 1976)*. 2017;42:520-524. doi:10.1097/BRS.0000000000001779
  30. Piper KF, Tomlinson SB, Santangelo G, et al. Risk factors for wound complications following spine surgery. *Surg Neurol Int*. 2017;8:269. doi:10.4103/sni.sni\_306\_17
  31. Fang A, Hu SS, Endres N, Bradford DS. Risk factors for infection after spinal surgery. *Spine (Phila Pa 1976)*. 2005;30:1460-1465. doi:10.1097/01.brs.0000166532.58227.4f
  32. Pesenti S, Pannu T, Andres-Bergos J, et al. What are the risk factors for surgical site infection after spinal fusion? *A meta-analysis*. *Eur Spine J*. 2018;27:2469-2480. doi:10.1007/s00586-018-5733-7
  33. Kerezoudis P, Alvi MA, Spinner RJ, Meyer FB, Habermann EB, Bydon M. Predictors of unplanned returns to the operating room within 30 days in neurosurgery: insights from a National Surgical Registry. *World Neurosurg*. 2019;123:e348-e370. doi:10.1016/j.wneu.2018.11.171
  34. Sørensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. *Ann Surg*. 2012;255:1069-1079. doi:10.1097/SLA.0b013e31824f632d
  35. Sandén B, Försth P, Michaëlsson K. Smokers show less improvement than nonsmokers two years after surgery for lumbar spinal stenosis: a study of 4555 patients from the Swedish spine register. *Spine (Phila Pa 1976)*. 2011;36:1059-1064. doi:10.1097/BRS.0b013e3181e92b36
  36. Chapin L, Ward K, Ryken T. Preoperative depression, smoking, and employment status are significant factors in patient satisfaction after lumbar spine surgery. *Clin Spine Surg*. 2017;30:E725-E732. doi:10.1097/BSD.0000000000000331

37. Seicean A, Seicean S, Alan N, et al. Effect of smoking on the perioperative outcomes of patients who undergo elective spine surgery. *Spine (Phila Pa 1976)*. 2013;38:1294-1302. doi:10.1097/BRS.0b013e31828e2747
38. Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. *Respir Care*. 2000;45:1200-1262.
39. Glassman SD, Anagnost SC, Parker A, Burke D, Johnson JR, Dimar JR. The effect of cigarette smoking and smoking cessation on spinal fusion. *Spine (Phila Pa 1976)*. 2000;25:2608-2615. doi:10.1097/00007632-200010150-00011
40. Jackson KL, Devine JG. The effects of smoking and smoking cessation on spine surgery: a systematic review of the literature. *Global Spine J*. 2016;6:695-701. doi:10.1055/s-0036-1571285
41. Møller AM, Villebro N, Pedersen T, Tønnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. *Lancet*. 2002;359:114-117. doi:10.1016/S0140-6736(02)07369-5
42. Mills E, Eyawo O, Lockhart I, Kelly S, Wu P, Ebbert JO. Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. *Am J Med*. 2011;124:144-154.e8. doi:10.1016/j.amjmed.2010.09.013